These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 34081269

  • 21. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment.
    Shi W, Blomain ES, Siglin J, Palmer JD, Dan T, Wang Y, Werner-Wasik M, Glass J, Kim L, Bar Ad V, Bhamidipati D, Evans JJ, Judy K, Farrell CJ, Andrews DW.
    J Neurooncol; 2018 Mar; 137(1):171-177. PubMed ID: 29235052
    [Abstract] [Full Text] [Related]

  • 22. Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
    Ghiaseddin A, Reardon D, Massey W, Mannerino A, Lipp ES, Herndon JE, McSherry F, Desjardins A, Randazzo D, Friedman HS, Peters KB.
    Oncologist; 2018 Feb; 23(2):157-e21. PubMed ID: 29133513
    [Abstract] [Full Text] [Related]

  • 23. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY.
    Neurology; 2008 Mar 04; 70(10):779-87. PubMed ID: 18316689
    [Abstract] [Full Text] [Related]

  • 24. Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis.
    Cho SJ, Kim HS, Suh CH, Park JE.
    Korean J Radiol; 2020 Jul 04; 21(7):908-918. PubMed ID: 32524791
    [Abstract] [Full Text] [Related]

  • 25. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
    Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt C, Zwirtes R, Sampson J, Weller M.
    JAMA Oncol; 2020 Jul 01; 6(7):1003-1010. PubMed ID: 32437507
    [Abstract] [Full Text] [Related]

  • 26. Efficacy of bevacizumab therapy in recurrent malignant gliomas in relation to the prior recurrence pattern or tumor location.
    Matsuda M, Ishikawa E, Yamamoto T, Akutsu H, Takano S, Matsumura A.
    J Clin Neurosci; 2017 Jun 01; 40():115-119. PubMed ID: 28246006
    [Abstract] [Full Text] [Related]

  • 27. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.
    Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, Ciampa A, Kesari S, Wen PY.
    Neuro Oncol; 2009 Oct 01; 11(5):550-5. PubMed ID: 19332770
    [Abstract] [Full Text] [Related]

  • 28. Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?
    Franceschi E, Lamberti G, Paccapelo A, Di Battista M, Genestreti G, Minichillo S, Mura A, Bartolini S, Agati R, Brandes AA.
    J Neurooncol; 2018 Sep 01; 139(2):383-388. PubMed ID: 29671196
    [Abstract] [Full Text] [Related]

  • 29. Bevacizumab use for recurrent high-grade glioma at McGill University Hospital.
    Sahebjam S, Garoufalis E, Guiot MC, Muanza T, Del Maestro R, Petrecca K, Sharma R, Kavan P.
    Can J Neurol Sci; 2013 Mar 01; 40(2):241-6. PubMed ID: 23419575
    [Abstract] [Full Text] [Related]

  • 30. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U, Sorensen M, Gaziel TB, Hasselbalch B, Poulsen HS.
    Anticancer Res; 2013 Apr 01; 33(4):1657-60. PubMed ID: 23564811
    [Abstract] [Full Text] [Related]

  • 31. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.
    Arvold ND, Shi DD, Aizer AA, Norden AD, Reardon DA, Lee EQ, Nayak L, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Wen PY, Alexander BM.
    J Neurooncol; 2017 Dec 01; 135(3):581-591. PubMed ID: 28975467
    [Abstract] [Full Text] [Related]

  • 32. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.
    Nagane M, Nishikawa R, Narita Y, Kobayashi H, Takano S, Shinoura N, Aoki T, Sugiyama K, Kuratsu J, Muragaki Y, Sawamura Y, Matsutani M.
    Jpn J Clin Oncol; 2012 Oct 01; 42(10):887-95. PubMed ID: 22844129
    [Abstract] [Full Text] [Related]

  • 33. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
    Hacibekiroglu I, Kodaz H, Erdogan B, Turkmen E, Ozcelik M, Esenkaya A, Saygi HM, Uzunoglu S, Cicin I.
    Med Oncol; 2015 Feb 01; 32(2):460. PubMed ID: 25572814
    [Abstract] [Full Text] [Related]

  • 34. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F, Guzzardi G, Del Sette B, Sponghini AP, Matheoud R, Soligo E, Trisoglio A, Carriero A, Stecco A.
    Neuroradiol J; 2019 Aug 01; 32(4):241-249. PubMed ID: 31066622
    [Abstract] [Full Text] [Related]

  • 35. Bevacizumab in recurrent high-grade pediatric gliomas.
    Narayana A, Kunnakkat S, Chacko-Mathew J, Gardner S, Karajannis M, Raza S, Wisoff J, Weiner H, Harter D, Allen J.
    Neuro Oncol; 2010 Sep 01; 12(9):985-90. PubMed ID: 20363768
    [Abstract] [Full Text] [Related]

  • 36. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
    Toh CH, Liau CT, Wei KC, Castillo M.
    J Neurooncol; 2019 Mar 01; 142(1):149-159. PubMed ID: 30535596
    [Abstract] [Full Text] [Related]

  • 37. The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma.
    Barajas RF, Butowski NA, Phillips JJ, Aghi MK, Berger MS, Chang SM, Cha S.
    Acad Radiol; 2016 Sep 01; 23(9):1073-82. PubMed ID: 27443507
    [Abstract] [Full Text] [Related]

  • 38. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.
    Reardon DA, Herndon JE, Peters K, Desjardins A, Coan A, Lou E, Sumrall A, Turner S, Sathornsumetee S, Rich JN, Boulton S, Lipp ES, Friedman HS, Vredenburgh JJ.
    J Neurooncol; 2012 Mar 01; 107(1):213-21. PubMed ID: 21997879
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The safety and efficacy of bevacizumab in treatment of recurrent low-grade glioma: a systematic review and meta-analysis.
    Habibi MA, Rashidi F, Gharedaghi H, Arshadi MR, Kazemivand S.
    Eur J Clin Pharmacol; 2024 Sep 01; 80(9):1259-1270. PubMed ID: 38733390
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.